The Lead Episode 171: A Discussion of the CMR Guide Trial
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered

In this episode of The Lead, host Jason T. Jacobson, MD, FHRS, is joined by Sei Iwai, MD, FHRS, and Jeanne E. Poole, MD, FHRS, CCDS, to discuss “Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%: The CMR GUIDE Randomized Clinical Trial.” The panel examines the trial’s findings on using cardiovascular magnetic resonance–identified myocardial scar to guide primary prevention ICD implantation, including limitations of the study and current approaches to sudden cardiac death risk stratification, as well as the potential role of more sophisticated, dynamic risk-prediction models.

  1. Describe the design, patient population, primary outcome, and key findings of the CMR GUIDE randomized clinical trial.

  2. Evaluate the limitations of using cardiovascular magnetic resonance–identified myocardial scar to guide primary prevention ICD implantation in patients with an LVEF of 36% to 50%.

  3. Assess current challenges and emerging approaches to sudden cardiac death risk stratification, including the potential use of multimodal and dynamic risk-prediction models.


Podcast Contributors

Host: Jason T. Jacobson, MD, FHRS

 

Guests: Sei Iwai, MD, FHRS and Jeanne E. Poole, MD, FHRS, CCDS

 

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

J. Jacobson

  • Honoraria/Speaking/Consulting Fee: Zoll Medical Corporation, Vektor Medical, Inc., CardioFocus, Inc., Abbott Medical, Johnson and Johnson

  • Stock Options-Privately Held: Atlas 5D


S. Iwai

  • Honoraria/Speaking/Consulting Fee: Alta Thera Pharmaceuticals, Biotronik, Johnson and Johnson, CardioFocus, Inc.

 

J. Poole

  • Honoraria/Speaking/Consulting Fee: Heart Rhythm Society

  • Research (Contracted Grants): Boston Scientific, AtriCure, Inc., Kestra, Inc., Biotronik




Staff Disclosu
re(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.
M. Baldwin: No relevant financial relationships with ineligible companies to disclose.